CBMPs were associated with significant improvements in anxiety, sleep quality and health-related quality of life, particularly under dried flowers.
Summary
UK Medical Cannabis Registry: n=1378 patients with prescribed CBMPs, improvements in GAD-7 (anxiety) at all time points (1, 3, 6, 12 months; p<0.010); dried flowers or combination showed stronger improvements than oil alone (p<0.050); 21,55% of patients reported adverse events.
P
PopulationPatients in the UK Medical Cannabis Registry who were prescribed Adven® CBMPs, n=1378
I
InterventionAdven® cannabis-based medicinal products (oils, dried flowers or combination), various forms of application
O
OutcomeImprovements in all PROMs (GAD-7, SQS, EQ-5D-5L) at all time points (1, 3, 6, 12 months), p<0,010; greatest improvements with dried flowers (alone or combined) vs. oil alone for GAD-7, SQS and EQ-5D-5L at 12 months (p<0,050)
Confidence in the evidence
Very lowLowModerateHigh
Low
The second of four GRADE levels, the effect estimate is of limited reliability.
Quality profile
Sample size★★★★★
Blinding—
Effect sizeClear benefit
Citations / year★★★★★
Authors
Erridge S, Leung O, Holvey C, Coomber R, Beri S, Khan S, Weatherall MW, Rucker JJ, Platt MW, Sodergren MH.
<h4>Introduction</h4>While there is increasing evidence of the effects of cannabis-based medicinal products (CBMPs) on health-related quality of life (HRQoL), a major limitation of the current literature is the heterogeneity of studied CBMPs. This study aims to analyze changes in HRQoL in patients prescribed a homogenous selection of CBMPs.<h4>Methods</h4>Primary outcomes were changes in patient-reported outcomes (PROMs) at 1, 3, 6, and 12 months from baseline. The secondary outcome was an adverse events analysis. Statistical significance was defined as p < 0.050.<h4>Results</h4>1378 patients prescribed Adven® CBMPs (Curaleaf International, Guernsey, UK) were included in the final analysis. 581 (42.16%) participants were current users of cannabis at baseline. 641 (46.51%), 235 (17.05%), and 502 (36.43%) patients were treated with oils, dried flowers, or a combination of the two, respectively. Improvements were found in all PROMs in each route of administration at 1, 3, 6, and 12 months from baseline (p < 0.010). Those prescribed dried flower only or both oils and dried flower experienced greater improvements in GAD-7, SQS, and EQ-5D-5L index values at 12 months (p < 0.050). There was no difference in outcomes between those prescribed dried flower only or dried flower with oils (p > 0.050). 3663 (265.82%) adverse events were reported by 297 (21.55%) patients.<h4>Conclusion</h4>There was an associated improvement in self-reported anxiety, sleep quality, and HRQoL in patients treated with the CBMPs. Those prescribed treatment formulations including dried flower were most likely to show a clinical improvement. However, these results must be interpreted with caution given the limitations of study design.